NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 4 FDA
NCT03064867 2022-11-16Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell LymphomaCase Comprehensive Cancer CenterPhase 1/2 Active not recruiting65 enrolled
NCT03886649 2022-04-01Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.Swiss Cancer InstitutePhase 1 Terminated7 enrolled